BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33008805)

  • 1. Soft Microenvironments Induce Chemoresistance by Increasing Autophagy Downstream of Integrin-Linked Kinase.
    Anlaş AA; Nelson CM
    Cancer Res; 2020 Oct; 80(19):4103-4113. PubMed ID: 33008805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannibalism, cell survival, and endocrine resistance in breast cancer.
    Clarke R
    Breast Cancer Res; 2011 Aug; 13(4):311. PubMed ID: 21884644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Antiestrogen-Promoted Pro-Survival Autophagy and Tamoxifen Resistance in Breast Cancer through Vitamin D Receptor.
    Li Y; Cook KL; Yu W; Jin L; Bouker KB; Clarke R; Hilakivi-Clarke L
    Nutrients; 2021 May; 13(5):. PubMed ID: 34069442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor variant ER-α36 promotes tamoxifen agonist activity in glioblastoma cells.
    Qu C; Ma J; Zhang Y; Han C; Huang L; Shen L; Li H; Wang X; Liu J; Zou W
    Cancer Sci; 2019 Jan; 110(1):221-234. PubMed ID: 30417588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells.
    Zhuang T; Zhu J; Li Z; Lorent J; Zhao C; Dahlman-Wright K; Strömblad S
    Oncotarget; 2015 Dec; 6(41):43853-68. PubMed ID: 26554417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of Estrogen-Regulated
    Zhang W; Wu M; Chong QY; Zhang M; Zhang X; Hu L; Zhong Y; Qian P; Kong X; Tan S; Li G; Ding K; Lobie PE; Zhu T
    Cancer Res; 2018 Sep; 78(17):4915-4928. PubMed ID: 29945962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
    Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
    J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators.
    Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A
    Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Icariin induces apoptosis by suppressing autophagy in tamoxifen-resistant breast cancer cell line MCF-7/TAM.
    Cheng X; Tan S; Duan F; Yuan Q; Li Q; Deng G
    Breast Cancer; 2019 Nov; 26(6):766-775. PubMed ID: 31172425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sliding p21-activated kinase 1 to nucleus impacts tamoxifen sensitivity.
    Rayala SK; Kumar R
    Biomed Pharmacother; 2007 Aug; 61(7):408-11. PubMed ID: 17604944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. O-GlcNAcylation-inducing treatments inhibit estrogen receptor α expression and confer resistance to 4-OH-tamoxifen in human breast cancer-derived MCF-7 cells.
    Kanwal S; Fardini Y; Pagesy P; N'tumba-Byn T; Pierre-Eugène C; Masson E; Hampe C; Issad T
    PLoS One; 2013; 8(7):e69150. PubMed ID: 23935944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
    Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC
    Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer.
    Wei C; Cao Y; Yang X; Zheng Z; Guan K; Wang Q; Tai Y; Zhang Y; Ma S; Cao Y; Ge X; Xu C; Li J; Yan H; Ling Y; Song T; Zhu L; Zhang B; Xu Q; Hu C; Bian XW; He X; Zhong H
    Proc Natl Acad Sci U S A; 2014 Feb; 111(5):E601-10. PubMed ID: 24449872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer.
    Cook KL; Wärri A; Soto-Pantoja DR; Clarke PA; Cruz MI; Zwart A; Clarke R
    Clin Cancer Res; 2014 Jun; 20(12):3222-32. PubMed ID: 24928945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.
    Yang F; Xie HY; Yang LF; Zhang L; Zhang FL; Liu HY; Li DQ; Shao ZM
    Autophagy; 2020 Jun; 16(6):1061-1076. PubMed ID: 32401166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy.
    Nagelkerke A; Sieuwerts AM; Bussink J; Sweep FC; Look MP; Foekens JA; Martens JW; Span PN
    Endocr Relat Cancer; 2014 Feb; 21(1):101-12. PubMed ID: 24434718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells.
    Shah YM; Al-Dhaheri M; Dong Y; Ip C; Jones FE; Rowan BG
    Mol Cancer Ther; 2005 Aug; 4(8):1239-49. PubMed ID: 16093440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.